Medical Equipment/Supplies/Accessories · Founded 1981 · www.gkb.net · BSE 533212 · NSE GKB OPHTHA · ISIN INE265D01015
No Notes Added Yet
Business
GKB Ophthalmics Ltd. is an Indian company primarily engaged in the manufacturing and supply of ophthalmic lenses, specifically spectacle lenses. The company produces a comprehensive range of finished and semi-finished lenses made from various materials (e.g., CR-39, polycarbonate) and designs (single vision, bifocal, progressive). They also offer specialized coatings such as anti-reflective, anti-scratch, UV protection, and blue-cut. GKB Ophthalmics operates predominantly on a business-to-business (B2B) model, supplying its products to opticians, distributors, and retail chains across India and to some international markets. Their revenue is generated through the sale of these manufactured lenses.
Revenue Mix
GKB Ophthalmics' core business revolves around ophthalmic lenses. While specific revenue contribution percentages for different lens types are not publicly detailed, their product portfolio broadly covers:
Single Vision Lenses: Standard lenses for a single prescription.
Bifocal & Progressive Lenses: Lenses offering multiple vision zones.
Specialized Lenses: Including photochromic (light-adaptive) and polarized lenses.
Coated Lenses: Lenses with various functional coatings (e.g., Multi Anti-Reflective, Hard Multicoat, Blue Cut, UV Protection).
Their business is predominantly domestic (India), with a smaller portion attributed to exports.
Industry
GKB Ophthalmics operates within the highly competitive Indian ophthalmic lens market, which is part of the broader medical equipment and supplies sector. The industry is characterized by the presence of large global players (e.g., EssilorLuxottica, Zeiss, Hoya) alongside several domestic manufacturers and importers. GKB Ophthalmics holds a significant position as one of the leading Indian manufacturers of spectacle lenses. They differentiate themselves through a wide product range, focus on quality, and an established pan-India distribution network catering to a vast number of opticians. They compete primarily on product innovation, pricing, and distribution reach.
MOAT
GKB Ophthalmics possesses several competitive advantages, though these may not be considered strong, impenetrable moats:
Established Manufacturing & Scale: As one of India's larger domestic lens manufacturers, they benefit from economies of scale in production compared to smaller players.
Extensive Distribution Network: A well-developed pan-India distribution network allows them deep market penetration and reach to a wide base of opticians.
Brand Recognition (B2B): Within the Indian optical trade, GKB has an established brand reputation for reliability and product range.
Product Portfolio: A comprehensive range of lenses across various materials, designs, and coatings allows them to cater to diverse customer needs.
Cost Efficiency: Being a domestic manufacturer can provide cost advantages in certain segments compared to importing finished lenses.
Growth Drivers
Key factors that can drive GKB Ophthalmics' growth over the next 3-5 years include:
Rising Eye Care Awareness: Increasing awareness about eye health and the importance of regular eye check-ups among the Indian population.
Growing Disposable Incomes: Higher disposable incomes allow consumers to invest in better quality and specialized lenses.
Aging Population: An increasing elderly population in India will naturally drive demand for vision correction solutions.
Digital Lifestyle: Prolonged screen time among all age groups contributes to an increase in vision problems, driving demand for protective and corrective lenses (e.g., blue-cut lenses).
Penetration into Tier 2/3 Cities: Expansion into underserved semi-urban and rural markets offers significant growth potential.
Product Innovation: Introduction of new lens technologies, materials, and coatings to meet evolving consumer demands and competition.
Risks
GKB Ophthalmics faces several business risks:
Intense Competition & Pricing Pressure: The presence of large multinational corporations and numerous domestic players leads to significant pricing pressure and can erode margins.
Raw Material Price Volatility: Reliance on imported raw materials (e.g., monomers) exposes the company to fluctuations in global commodity prices and foreign exchange rates.
Technological Obsolescence: Rapid advancements in lens technology and manufacturing processes could render existing products or manufacturing techniques less competitive.
Economic Slowdown: As spectacle lenses can be considered a discretionary purchase, an economic downturn could impact consumer spending and demand for higher-value lenses.
Regulatory Changes: Changes in import duties, taxes, or quality standards for medical devices could impact operations and profitability.
Dependency on B2B Channel: Heavy reliance on opticians and distributors means that strong relationships and efficient channel management are critical; any disruption could impact sales.
Management & Ownership
GKB Ophthalmics Ltd. is promoted by the GKB family, who have a long-standing presence in the Indian ophthalmic industry. The company is primarily promoter-managed, with the family holding a significant stake in the company. This indicates a strong alignment of interests between the management and shareholders. Further details on specific management quality would require a deeper dive into their corporate governance, past performance, and strategic decisions. As of public records, the promoter holding is substantial, reflecting a closely held nature of the business.
Outlook
GKB Ophthalmics is positioned in a growing market driven by demographic trends and increasing health awareness in India. The company's established manufacturing base and extensive distribution network provide a solid foundation for capitalizing on this growth.
The bull case hinges on the increasing demand for eye care products in India due to factors like an aging population, rising disposable incomes, and widespread digital screen usage. GKB's ability to innovate its product portfolio, expand its reach into underserved markets, and maintain cost efficiencies could drive sustainable growth.
Conversely, the bear case points to intense competition from global giants and domestic players, which can lead to pricing pressures and margin erosion. The company's exposure to raw material price volatility and potential technological disruption in the ophthalmic lens market also pose significant challenges. Sustained success will depend on its ability to navigate these competitive and operational headwinds effectively while leveraging its domestic market strengths.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 22 | 26 | 26 | 26 | 31 | 32 | 30 | 57 | 30 | 33 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Total Income | 22 | 26 | 26 | 26 | 31 | 33 | 31 | 58 | 31 | 34 |
| Total Expenditure | 22 | 25 | 26 | 27 | 34 | 31 | 27 | 55 | 27 | 30 |
| Operating Profit | 1 | 1 | 0 | -0 | -3 | 1 | 3 | 2 | 4 | 3 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
| Profit Before Tax | -1 | 0 | -1 | -2 | -4 | -1 | 2 | 1 | 1 | 2 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 |
| Profit After Tax | -1 | -0 | -1 | -2 | -4 | -1 | 2 | 1 | 1 | 2 |
| Adjustments | 0 | -0 | -0 | -0 | 1 | -0 | -0 | -0 | -1 | -1 |
| Profit After Adjustments | -1 | -0 | -1 | -2 | -4 | -1 | 2 | 0 | 0 | 1 |
| Adjusted Earnings Per Share | -1.8 | -0.5 | -2.4 | -4 | -7 | -2 | 3.2 | 0.9 | 0.4 | 2 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 44 | 74 | 77 | 57 | 59 | 57 | 71 | 75 | 88 | 109 | 149 | 150 |
| Other Income | 2 | 1 | 0 | 2 | 0 | 2 | 1 | 1 | 2 | 1 | 2 | 3 |
| Total Income | 46 | 75 | 78 | 59 | 59 | 59 | 72 | 76 | 90 | 110 | 151 | 154 |
| Total Expenditure | 46 | 72 | 76 | 56 | 56 | 55 | 66 | 72 | 88 | 112 | 140 | 139 |
| Operating Profit | 0 | 3 | 2 | 3 | 3 | 4 | 6 | 5 | 2 | -1 | 11 | 12 |
| Interest | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 3 | 4 |
| Depreciation | 1 | 1 | 2 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Exceptional Income / Expenses | 11 | 3 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | -2 | -1 |
| Profit Before Tax | 8 | 3 | -1 | -2 | -2 | -1 | 2 | 0 | -3 | -7 | 3 | 6 |
| Provision for Tax | 4 | 0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 4 | 3 | -1 | -1 | -2 | -1 | 2 | 0 | -3 | -7 | 3 | 6 |
| Adjustments | 0 | 0 | 0 | 0 | 1 | -0 | -1 | -0 | 0 | 0 | -2 | -2 |
| Profit After Adjustments | 4 | 3 | -1 | -1 | -2 | -1 | 1 | -0 | -3 | -7 | 1 | 3 |
| Adjusted Earnings Per Share | 9.5 | 6.2 | -2.3 | -2.4 | -3.6 | -1.8 | 2.5 | -0.3 | -5.6 | -14 | 2.4 | 6.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 37% | 26% | 21% | 13% |
| Operating Profit CAGR | 0% | 30% | 22% | 0% |
| PAT CAGR | 0% | 0% | 0% | -3% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -1% | -14% | -6% | -7% |
| ROE Average | 6% | -4% | -2% | -0% |
| ROCE Average | 9% | 0% | 2% | 3% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 45 | 47 | 45 | 55 | 59 | 63 | 63 | 63 | 60 | 52 | 53 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 5 | 4 | 4 | 2 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 3 | 2 |
| Other Non-Current Liabilities | 2 | 2 | 2 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 |
| Total Current Liabilities | 23 | 37 | 36 | 37 | 41 | 38 | 39 | 41 | 46 | 62 | 71 |
| Total Liabilities | 69 | 86 | 83 | 97 | 106 | 111 | 114 | 116 | 118 | 129 | 136 |
| Fixed Assets | 13 | 18 | 18 | 26 | 26 | 24 | 23 | 19 | 18 | 17 | 15 |
| Other Non-Current Assets | 5 | 2 | 1 | 7 | 7 | 13 | 16 | 13 | 13 | 13 | 13 |
| Total Current Assets | 51 | 66 | 64 | 64 | 73 | 74 | 76 | 84 | 87 | 99 | 108 |
| Total Assets | 69 | 86 | 83 | 97 | 106 | 111 | 114 | 116 | 118 | 129 | 136 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 3 | 3 | 2 | 2 | 9 | 13 | 6 | 6 | 2 | 3 | 3 |
| Cash Flow from Operating Activities | -11 | -3 | -3 | 4 | 3 | 7 | 5 | -3 | 4 | -3 | -4 |
| Cash Flow from Investing Activities | 15 | 4 | 1 | -10 | -4 | -17 | -4 | 1 | -2 | 3 | 9 |
| Cash Flow from Financing Activities | -3 | -1 | 1 | 13 | 4 | 3 | -2 | -2 | -2 | 1 | -6 |
| Net Cash Inflow / Outflow | 0 | -1 | 0 | 7 | 4 | -7 | -0 | -4 | 1 | -0 | -0 |
| Closing Cash & Cash Equivalent | 3 | 2 | 2 | 9 | 13 | 6 | 6 | 2 | 3 | 3 | 3 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 9.51 | 6.23 | -2.34 | -2.38 | -3.65 | -1.8 | 2.53 | -0.33 | -5.58 | -13.98 | 2.42 |
| CEPS(Rs) | 13.1 | 9.68 | 1.75 | 4.99 | 2.32 | 4.75 | 9.15 | 5.84 | -0.17 | -7.92 | 12.43 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 107.89 | 112.64 | 108.2 | 111.84 | 117.55 | 124.3 | 125.18 | 124.38 | 118.58 | 103.24 | 104.82 |
| Core EBITDA Margin(%) | -3.82 | 2.39 | 1.72 | 2 | 3.65 | 3.37 | 6.83 | 4.88 | 0.66 | -2.55 | 5.78 |
| EBIT Margin(%) | 20.91 | 5.54 | 0.18 | -0.37 | -1.69 | 1.94 | 4.83 | 2.4 | -0.99 | -4 | 3.88 |
| Pre Tax Margin(%) | 17.33 | 3.85 | -1.46 | -2.97 | -4.19 | -1.63 | 2.74 | 0.18 | -3.15 | -6.17 | 2.08 |
| PAT Margin (%) | 8.67 | 3.38 | -1.25 | -2.14 | -4.19 | -1.32 | 2.74 | 0.15 | -3.38 | -6.5 | 2.03 |
| Cash Profit Margin (%) | 11.93 | 5.26 | 0.93 | 4.05 | 2 | 4.21 | 6.5 | 3.9 | -0.09 | -3.66 | 4.2 |
| ROA(%) | 5.48 | 3.34 | -1.15 | -1.36 | -2.41 | -0.69 | 1.73 | 0.1 | -2.55 | -5.72 | 2.28 |
| ROE(%) | 9.32 | 5.65 | -2.12 | -2.52 | -4.41 | -1.23 | 3.09 | 0.18 | -4.87 | -12.66 | 5.77 |
| ROCE(%) | 18.94 | 7.99 | 0.25 | -0.34 | -1.38 | 1.48 | 4.58 | 2.44 | -1.2 | -6.32 | 8.82 |
| Receivable days | 142.03 | 99.83 | 122.19 | 162.83 | 151.07 | 142.44 | 100.29 | 114.24 | 116.09 | 90.24 | 86.14 |
| Inventory Days | 169.82 | 124.36 | 147.17 | 190.76 | 181.31 | 211.22 | 188.1 | 184.84 | 162.86 | 151.37 | 128.56 |
| Payable days | 192.73 | 126.99 | 165.17 | 231.94 | 221.09 | 234.2 | 200.8 | 190.02 | 173.79 | 179.85 | 165.5 |
| PER(x) | 6.94 | 21.4 | 0 | 0 | 0 | 0 | 36.39 | 0 | 0 | 0 | 21.72 |
| Price/Book(x) | 0.61 | 1.18 | 1.07 | 0.83 | 0.37 | 0.66 | 0.73 | 0.87 | 0.74 | 0.58 | 0.5 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.7 | 0.81 | 0.72 | 0.82 | 0.39 | 0.63 | 0.59 | 0.68 | 0.43 | 0.29 | 0.22 |
| EV/Core EBITDA(x) | 626.24 | 19.06 | 30.3 | 14.15 | 8.74 | 8.29 | 6.95 | 11.17 | 18.04 | -21.42 | 3.06 |
| Net Sales Growth(%) | 24.38 | 69.3 | 4.5 | -26.17 | 2.4 | -2.83 | 24.72 | 6.4 | 16.93 | 23.49 | 36.77 |
| EBIT Growth(%) | 2193.92 | -55.59 | -96.77 | -255.89 | -362.64 | 211.85 | 210.17 | -47.08 | -148.14 | -399.13 | 232.67 |
| PAT Growth(%) | 400.08 | -34.53 | -137.52 | -25.86 | -100.59 | 69.46 | 359.73 | -94.02 | -2664.14 | -137.39 | 142.76 |
| EPS Growth(%) | 0 | -34.53 | -137.52 | -1.8 | -53.4 | 50.67 | 240.42 | -113.14 | -1578.92 | -150.66 | 117.3 |
| Debt/Equity(x) | 0.16 | 0.15 | 0.22 | 0.27 | 0.26 | 0.19 | 0.19 | 0.18 | 0.19 | 0.28 | 0.22 |
| Current Ratio(x) | 2.25 | 1.8 | 1.75 | 1.72 | 1.76 | 1.94 | 1.95 | 2.03 | 1.89 | 1.59 | 1.52 |
| Quick Ratio(x) | 1.32 | 0.96 | 0.87 | 0.97 | 1.02 | 1.01 | 0.98 | 1.09 | 1.03 | 0.79 | 0.75 |
| Interest Cover(x) | 5.84 | 3.28 | 0.11 | -0.14 | -0.67 | 0.54 | 2.32 | 1.08 | -0.46 | -1.84 | 2.16 |
| Total Debt/Mcap(x) | 0.26 | 0.13 | 0.21 | 0.33 | 0.7 | 0.29 | 0.25 | 0.21 | 0.26 | 0.48 | 0.44 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.95 | 50.95 | 50.98 | 50.99 | 51.06 | 51.06 | 51.13 | 51.13 | 51.15 | 51.15 |
| FII | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 47.27 | 47.27 | 47.23 | 47.23 | 47.16 | 47.16 | 47.09 | 47.09 | 47.07 | 47.07 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 |
| FII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +37% | +26% | +21% | +13% |
| Operating Profit CAGR | — | +30% | +22% | — |
| PAT CAGR | — | — | — | -3% |
| Share Price CAGR | -1% | -14% | -6% | -7% |
| ROE Average | +6% | -4% | -2% | 0% |
| ROCE Average | +9% | 0% | +2% | +3% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.95 | 50.95 | 50.98 | 50.99 | 51.06 | 51.06 | 51.13 | 51.13 | 51.15 | 51.15 |
| FII | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 47.27 | 47.27 | 47.23 | 47.23 | 47.16 | 47.16 | 47.09 | 47.09 | 47.07 | 47.07 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 |
| FII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.